Amylyx Pharmaceuticals Inc
NASDAQ:AMLX

Watchlist Manager
Amylyx Pharmaceuticals Inc Logo
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Watchlist
Price: 4.05 USD 2.27% Market Closed
Market Cap: 277.6m USD
Have any thoughts about
Amylyx Pharmaceuticals Inc?
Write Note

Amylyx Pharmaceuticals Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Amylyx Pharmaceuticals Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Accounts Payable
$22.1m
CAGR 3-Years
83%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accounts Payable
$9B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Accounts Payable
$3.5B
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
3%
Pfizer Inc
NYSE:PFE
Accounts Payable
$5.1B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
6%
Merck & Co Inc
NYSE:MRK
Accounts Payable
$3.6B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accounts Payable
$2.9B
CAGR 3-Years
23%
CAGR 5-Years
21%
CAGR 10-Years
11%
No Stocks Found

Amylyx Pharmaceuticals Inc
Glance View

Market Cap
277.6m USD
Industry
Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2022-01-07. The firm is developing therapies for treatment paradigm for amyotrophic lateral sclerosis (ALS), and range of neurodegenerative diseases by keeping neurons alive. The firm is pursuing commercialization of its product candidate, AMX0035. AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO) also known as ursodoxicoltaurine. AMX0035 is designed to target the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. AMX0035 keep neurons alive under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of Alzheimer’s Disease (AD) and multiple sclerosis.

AMLX Intrinsic Value
1.42 USD
Overvaluation 65%
Intrinsic Value
Price

See Also

What is Amylyx Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
22.1m USD

Based on the financial report for Dec 31, 2023, Amylyx Pharmaceuticals Inc's Accounts Payable amounts to 22.1m USD.

What is Amylyx Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
83%

Over the last year, the Accounts Payable growth was 250%. The average annual Accounts Payable growth rates for Amylyx Pharmaceuticals Inc have been 83% over the past three years .

Back to Top